Cargando…

Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis

Fibrosis is a common pathway followed by different organs after injury, and it can lead to parenchymal scarring, cellular dysfunction, and even organ failure. The NLRP3 inflammasome is a multiprotein complex composed of the sensor molecule NLRP3, the adaptor apoptosis-associated speck-like protein c...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Nan, Wei, Bo, Fu, Xiaohui, Wang, Chuan, Wu, Yimou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773645/
https://www.ncbi.nlm.nih.gov/pubmed/33390969
http://dx.doi.org/10.3389/fphar.2020.591393
_version_ 1783630088265269248
author Ding, Nan
Wei, Bo
Fu, Xiaohui
Wang, Chuan
Wu, Yimou
author_facet Ding, Nan
Wei, Bo
Fu, Xiaohui
Wang, Chuan
Wu, Yimou
author_sort Ding, Nan
collection PubMed
description Fibrosis is a common pathway followed by different organs after injury, and it can lead to parenchymal scarring, cellular dysfunction, and even organ failure. The NLRP3 inflammasome is a multiprotein complex composed of the sensor molecule NLRP3, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and the effector protease caspase-1. Overactivation of the NLRP3 inflammasome triggers the abundant secretion of IL-1β and IL-18, induces pyroptosis, and promotes the release of a swathe of proinflammatory proteins, all of which contribute to fibrogenic processes in multiple organs. In recent years, screening bioactive natural compounds for NLRP3 inhibitors to alleviate fibrosis has gained broad interest from the scientific community because of the associated cost-effectiveness and easy access. In this review, we systematically and comprehensively summarize the natural products, including terpenoids, phenols, and alkaloids, among others, and the plant-derived crude extracts, that have been reported to ameliorate fibrosis via inhibiting NLRP3 inflammasome activation and highlight the underlying mechanisms. Among all the compounds, diterpenoids is the most promising candidates for inhibiting NLRP3 inflammasome activation and improving fibrosis, as they possess combined inhibitory effect on NLRP3 inflammasome assembly and NF-κB signaling pathway. All the information may aid in the development of therapeutic strategies for the treatment of fibrotic diseases.
format Online
Article
Text
id pubmed-7773645
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77736452021-01-01 Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis Ding, Nan Wei, Bo Fu, Xiaohui Wang, Chuan Wu, Yimou Front Pharmacol Pharmacology Fibrosis is a common pathway followed by different organs after injury, and it can lead to parenchymal scarring, cellular dysfunction, and even organ failure. The NLRP3 inflammasome is a multiprotein complex composed of the sensor molecule NLRP3, the adaptor apoptosis-associated speck-like protein containing a CARD (ASC), and the effector protease caspase-1. Overactivation of the NLRP3 inflammasome triggers the abundant secretion of IL-1β and IL-18, induces pyroptosis, and promotes the release of a swathe of proinflammatory proteins, all of which contribute to fibrogenic processes in multiple organs. In recent years, screening bioactive natural compounds for NLRP3 inhibitors to alleviate fibrosis has gained broad interest from the scientific community because of the associated cost-effectiveness and easy access. In this review, we systematically and comprehensively summarize the natural products, including terpenoids, phenols, and alkaloids, among others, and the plant-derived crude extracts, that have been reported to ameliorate fibrosis via inhibiting NLRP3 inflammasome activation and highlight the underlying mechanisms. Among all the compounds, diterpenoids is the most promising candidates for inhibiting NLRP3 inflammasome activation and improving fibrosis, as they possess combined inhibitory effect on NLRP3 inflammasome assembly and NF-κB signaling pathway. All the information may aid in the development of therapeutic strategies for the treatment of fibrotic diseases. Frontiers Media S.A. 2020-12-17 /pmc/articles/PMC7773645/ /pubmed/33390969 http://dx.doi.org/10.3389/fphar.2020.591393 Text en Copyright © 2020 Ding, Wei, Fu, Wang and Wu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ding, Nan
Wei, Bo
Fu, Xiaohui
Wang, Chuan
Wu, Yimou
Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title_full Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title_fullStr Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title_full_unstemmed Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title_short Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
title_sort natural products that target the nlrp3 inflammasome to treat fibrosis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7773645/
https://www.ncbi.nlm.nih.gov/pubmed/33390969
http://dx.doi.org/10.3389/fphar.2020.591393
work_keys_str_mv AT dingnan naturalproductsthattargetthenlrp3inflammasometotreatfibrosis
AT weibo naturalproductsthattargetthenlrp3inflammasometotreatfibrosis
AT fuxiaohui naturalproductsthattargetthenlrp3inflammasometotreatfibrosis
AT wangchuan naturalproductsthattargetthenlrp3inflammasometotreatfibrosis
AT wuyimou naturalproductsthattargetthenlrp3inflammasometotreatfibrosis